InMed Pharmaceuticals (FRA:MWG) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is InMed Pharmaceuticals LT-Debt-to-Total-Asset?

InMed Pharmaceuticals FRA:MWG +0.72% 29 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates FRA:MWG with a GF Score™ of 29/100 and a GF Value™ of €0.78. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. InMed Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

InMed Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.05) to Mar. 2026 (0.00). It may suggest that InMed Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

InMed Pharmaceuticals (FRA:MWG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

InMed Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

InMed Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals LT-Debt-to-Total-Asset Chart

InMed Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.03

0.00

0.06

0.02

InMed Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.02	0.02	0.01	0.00

29GF Score

InMed Pharmaceuticals Inc FRA:MWG

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

InMed Pharmaceuticals LT-Debt-to-Total-Asset Calculation

InMed Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )	/	Total Assets (A: Jun. 2025 )
	=	0.265	/	13.508
	=	0.02

InMed Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.027	/	7.901
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

InMed Pharmaceuticals (FRA:MWG) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on InMed Pharmaceuticals and its competitors.

Is InMed Pharmaceuticals' LT-Debt-to-Total-Asset too high?

InMed Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.00. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does InMed Pharmaceuticals' LT-Debt-to-Total-Asset compare to SNOA and CVSI?

InMed Pharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is InMed Pharmaceuticals stock overvalued right now?

InMed Pharmaceuticals (FRA:MWG) has a current LT-Debt-to-Total-Asset of 0.00. The stock's GF Value™ is €0.78, compared to a current price of €1.40 — trading 79.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For InMed Pharmaceuticals (FRA:MWG), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of €1.40 is trading 79.5% above its estimated GF Value™ of €0.78.

Key valuation signals for FRA:MWG:

LT-Debt-to-Total-Asset: 0.00
GF Value™: €0.78 vs. price of €1.40 (79.5% above fair value)
GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InMed Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SNOA CVSI PRFX SBFM CTTH BUDZ LVRLF GELS YCBD CBIH XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges INM:USA

Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8

Website https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.

29GF Score

Get the complete analysis for FRA:MWG

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.40

Price

€0.78

GF Value

View FRA:MWG Analysis

See LT-Debt-to-Total-Asset data for all stocks →